Diligence memo · auto-generated · as of July 3, 2026
Blue Lake Biotechnology, Inc.
Blue Lake Biotechnology, Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Blue Lake Biotechnology, Inc. operates in Biotechnology, based in ATHENS.
Sub-sector tags: biotech.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Blue Lake Biotechnology, Inc. has raised $19M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $10M on 2022-04-09.
Most recent recorded round closed around 2022-04-09.
Valuation (modeled)modeled
Provath models Blue Lake Biotechnology, Inc. at approximately $154M (range $11M–$556M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 3.47× the median modeled value of Series A Biotechnology companies in 2022–2024 (303 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 14 months.
Last raise 4.2 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 1.7× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 67% of Biotechnology peers (4293 compared).
Modeled value ranks above 67% of those peers.
Closest niche peers: GeoVax Labs, Inc., Cellinfinity Bio Holding Company, LLC, Adient Medical, Inc., Entegrion Inc, BCD Bioscience, Inc..
Peoplefiled
5 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.